355 related articles for article (PubMed ID: 34667157)
1. Signaling pathways in the regulation of cytokine release syndrome in human diseases and intervention therapy.
Li X; Shao M; Zeng X; Qian P; Huang H
Signal Transduct Target Ther; 2021 Oct; 6(1):367. PubMed ID: 34667157
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 Causes a Different Cytokine Response Compared to Other Cytokine Storm-Causing Respiratory Viruses in Severely Ill Patients.
Olbei M; Hautefort I; Modos D; Treveil A; Poletti M; Gul L; Shannon-Lowe CD; Korcsmaros T
Front Immunol; 2021; 12():629193. PubMed ID: 33732251
[TBL] [Abstract][Full Text] [Related]
3. Clinical characterization and risk factors associated with cytokine release syndrome induced by COVID-19 and chimeric antigen receptor T-cell therapy.
Hong R; Zhao H; Wang Y; Chen Y; Cai H; Hu Y; Wei G; Huang H
Bone Marrow Transplant; 2021 Mar; 56(3):570-580. PubMed ID: 32943758
[TBL] [Abstract][Full Text] [Related]
4. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.
Acharya UH; Dhawale T; Yun S; Jacobson CA; Chavez JC; Ramos JD; Appelbaum J; Maloney DG
Expert Rev Hematol; 2019 Mar; 12(3):195-205. PubMed ID: 30793644
[TBL] [Abstract][Full Text] [Related]
5. Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy.
Iovino L; Thur LA; Gnjatic S; Chapuis A; Milano F; Hill JA
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986127
[TBL] [Abstract][Full Text] [Related]
6. The immunologic aspects of cytokine release syndrome and graft versus host disease following CAR T cell therapy.
Mansouri V; Yazdanpanah N; Rezaei N
Int Rev Immunol; 2022; 41(6):649-668. PubMed ID: 34607523
[TBL] [Abstract][Full Text] [Related]
7. Interindividual immunogenic variants: Susceptibility to coronavirus, respiratory syncytial virus and influenza virus.
Darbeheshti F; Mahdiannasser M; Uhal BD; Ogino S; Gupta S; Rezaei N
Rev Med Virol; 2021 Nov; 31(6):e2234. PubMed ID: 33724604
[TBL] [Abstract][Full Text] [Related]
8. Predictive role of endothelial cell activation in cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukaemia.
Hong F; Shi M; Cao J; Wang Y; Gong Y; Gao H; Li Z; Zheng J; Zeng L; He A; Xu K
J Cell Mol Med; 2021 Dec; 25(24):11063-11074. PubMed ID: 34734474
[TBL] [Abstract][Full Text] [Related]
9. Cytokine Release Syndrome Biology and Management.
Cobb DA; Lee DW
Cancer J; 2021 Mar-Apr 01; 27(2):119-125. PubMed ID: 33750071
[TBL] [Abstract][Full Text] [Related]
10. Targeting Cytokine Storm to Manage Patients with COVID-19: A Mini-Review.
Roshanravan N; Seif F; Ostadrahimi A; Pouraghaei M; Ghaffari S
Arch Med Res; 2020 Oct; 51(7):608-612. PubMed ID: 32682575
[TBL] [Abstract][Full Text] [Related]
11. Influenza infection, SARS, MERS and COVID-19: Cytokine storm - The common denominator and the lessons to be learned.
Ryabkova VA; Churilov LP; Shoenfeld Y
Clin Immunol; 2021 Feb; 223():108652. PubMed ID: 33333256
[TBL] [Abstract][Full Text] [Related]
12. Case Report: Local Cytokine Release Syndrome in an Acute Lymphoblastic Leukemia Patient After Treatment With Chimeric Antigen Receptor T-Cell Therapy: A Possible Model, Literature Review and Perspective.
Luan C; Zhou J; Wang H; Ma X; Long Z; Cheng X; Chen X; Huang Z; Zhang D; Xia R; Ge J
Front Immunol; 2021; 12():707191. PubMed ID: 34349766
[TBL] [Abstract][Full Text] [Related]
13. IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome.
Kang S; Tanaka T; Inoue H; Ono C; Hashimoto S; Kioi Y; Matsumoto H; Matsuura H; Matsubara T; Shimizu K; Ogura H; Matsuura Y; Kishimoto T
Proc Natl Acad Sci U S A; 2020 Sep; 117(36):22351-22356. PubMed ID: 32826331
[TBL] [Abstract][Full Text] [Related]
14. Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.
Yan Z; Zhang H; Cao J; Zhang C; Liu H; Huang H; Cheng H; Qiao J; Wang Y; Wang Y; Gao L; Shi M; Sang W; Zhu F; Li D; Sun H; Wu Q; Qi Y; Li H; Wang X; Li Z; Liu H; Zheng J; Qian W; Zhang X; Xu K
Front Immunol; 2021; 12():611366. PubMed ID: 33708205
[TBL] [Abstract][Full Text] [Related]
15. COVID-19 in patients with cancer: Risks and precautions.
Razavi A; Hamblin MR; Rezaei N
Am J Emerg Med; 2021 Oct; 48():357-360. PubMed ID: 33546958
[TBL] [Abstract][Full Text] [Related]
16. Management Principles Associated With Cytokine Release Syndrome.
Baer B; Dudley CV; Simons RM
Semin Oncol Nurs; 2019 Oct; 35(5):150931. PubMed ID: 31477411
[TBL] [Abstract][Full Text] [Related]
17. Cytokine release syndrome after allogeneic stem cell transplantation with posttransplant cyclophosphamide.
Solán L; Landete E; Bailén R; Dorado N; Oarbeascoa G; Anguita J; Díez-Martín JL; Kwon M
Hematol Oncol; 2020 Oct; 38(4):597-603. PubMed ID: 32592410
[TBL] [Abstract][Full Text] [Related]
18. Potential Pathophysiological Mechanisms Underlying Multiple Organ Dysfunction in Cytokine Release Syndrome.
Chen P; Tang Y; He W; Yang R; Lan Z; Chen R; Zhang P
Mediators Inflamm; 2022; 2022():7137900. PubMed ID: 35431655
[TBL] [Abstract][Full Text] [Related]
19. Cytokine Release Syndrome during Antithymocyte Globulin/Anti-T Lymphocyte Globulin Serotherapy for Graft-versus-Host Disease Prophylaxis before Allogeneic Hematopoietic Stem Cell Transplantation: Incidence and Early Clinical Impact According to American Society of Transplantation and Cellular Therapy Grading Criteria.
Knaus HA; Rottner T; Baumann CK; Cserna J; Mitterbauer M; Schulenburg A; Rabitsch W; Wohlfarth P
Transplant Cell Ther; 2022 May; 28(5):260.e1-260.e9. PubMed ID: 35217212
[TBL] [Abstract][Full Text] [Related]
20. Cytokine Release Syndrome Associated with T-Cell-Based Therapies for Hematological Malignancies: Pathophysiology, Clinical Presentation, and Treatment.
Cosenza M; Sacchi S; Pozzi S
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
